Boston Scientific Prices €900,000,000 of Senior Notes Boston Scientific Corporation (the Company ) (NYSE: BSX) announced the pricing of a public offering of €900,000,000 aggregate principal amount of...

MARLBOROUGH, Mass. , Nov. 6, 2019 /PRNewswire/ -- Boston Scientific Corporation (the "Company") (NYSE: BSX ) announced the pricing of a public offering of €900,000,000 aggregate principal amount of its 0.625% notes due 2027, under the Company's shelf registration statement.

The Company expects to receive the net offering proceeds upon closing on November 12, 2019 , subject to customary closing conditions. The Company intends to use the net proceeds from the offering to (i) fund the previously announced tender offer for up to $1.0 billion in aggregate principal amount of certain series of the Company's senior notes (the "Tender Offer") and (ii) pay accrued and unpaid interest, premiums, fees and expenses in connection with the Tender Offer. The Company intends to use any remaining proceeds for repayment of other indebtedness and general corporate purposes.

Nothing herein shall constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification under the securities laws of any such state or jurisdiction. The offering is being made by means of a prospectus and related preliminary prospectus supplement only, copies of which or information concerning this offering may be obtained by contacting the joint book-running managers: Barclays Bank PLC, toll-free at 1-888-603-5847; Goldman Sachs & Co. LLC, toll-free at 1-866-471-2526, or Merrill Lynch International, toll-free at +1-800-294-1322.

About Boston Scientific Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for 40 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare.

Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our proposed offering and intended use of proceeds. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

SOURCE Boston Scientific Corporation